Lexicon Pharmaceuticals LXRX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Lexicon Pharmaceuticals (LXRX) reported accretion (amortization) of discounts and premiums, investments of $562K in Q1 2026.
- How has Lexicon Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Lexicon Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 57.6% year-over-year, from $1.33M to $562K.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to net income for the amortization of premiums or the accretion of discounts on investment securities held by the company. It reflects the systematic recognition of the difference between the purchase price and the par value of debt securities over their remaining term. This adjustment is essential for reconciling net income to cash flow from operations by removing the impact of these non-cash yield adjustments.